Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS).

Next Previous
X
Search
Trial Profile

A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cryopyrin-associated periodic syndromes
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 02 Jul 2019 The trial is competed at France (End Date: 19 Nov 2014), as per European Clinical Trials Database record.
    • 13 Jun 2015 Interim results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 10 Jun 2015 Results of the efficacy and effects of canakinumab on post-vaccination antibody titer were presented at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top